This dataset consolidates the pharmaceutical lists which NHS England has a regulatory duty to prepare, maintain and publish for each Health and Wellbeing Board area. This consolidated list includes lists of: NHS pharmacies (also known as NHS community pharmacies) and; NHS appliance contractors (also known as NHS dispensing appliance contractors) and; Local Pharmaceutical Services contractors Pharmaceutical lists for each Health and Wellbeing Board area are maintained by NHS England by pharmacy contract teams. Community pharmacies and dispensing appliance contractors can apply to or notify contract teams to amend the details held by the regional teams as specified in The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 . Further details on the application processes can be found on the Primary Care Support England website. NHSBSA collates information on changes from NHS pharmacy contract teams and PCSE in the consolidated pharmaceutical list on NHS England's behalf. Typically, high volumes of changes take place each month; and so, the consolidated pharmaceutical list is produced and validated on a quarterly basis. This validation confirms the accuracy of the consolidated pharmaceutical list, by comparing it to the pharmaceutical lists maintained for each Health and Wellbeing Board area. The consolidated pharmaceutical list here represents the data as recorded in the NHSBSA Master Data Replacement System (MDR) on the last day of each quarter. Where information contained in the published list is discovered to be incorrect after publication, backdated amendments are made and reflected in the next publication. We publish the related dataset Pharmacy Openings and Closures on a monthly basis.

A list of medicinal products containing the names of registered medicinal products with their maximum retail selling price. The list for each medicinal product includes the following fields: (a) Pricing Code (b) Name of Pharmaceutical Product (c) Packaging (d) Active Ingredient (e) Marketing Authorisation Holder (f) Authorised Local Pricing Representative (g) Maximum Price Incl VAT

The National Prescribed Drug Register provides the basis for the official statistics about prescribed drugs in Sweden.

The National Prescribed Drug Register with personal identity numbers was established in July 2005 and contains all prescribed drugs dispensed at pharmacies. About 67 percent (6.8 million) of the population were prescribed a pharmaceutical at least once 2019. Each row in the register corresponds to one dispensation at a pharmacy. The number of rows in the register amounts to more than 100 million per year. This level has remained almost unchanged for several years.

The purpose of the Swedish Prescribed Drug Register is to increase the patient safety in the pharmaceutical area. The register is used by researchers, media, analysts in the regions and authorities as well as by the pharmaceutical industry. The register can be linked to other health data registers, for example the National Patient Register or the National Medical Birth Register. Increased knowledge of the effects and safety of different drugs may be of benefit to each individual patient in the long run.

The register is updated each month with new data from the Swedish eHealth Agency based on the monthly billing of the pharmacies. The register contains all prescribed drugs that are dispensed at pharmacies as well as information on dispensed medical devices and medical consumables within the pharmaceutical benefits scheme, such as ostomy products and foods for nutritional use by children under 16 years.

Drugs administered at hospital settings or nursing homes are not included in the register. Vaccines and over-the-counter medicines are not included in the register. In the register it is not possible to identify individual prescribers or the individual prescriber’s workplace.

The register contains information about

• patient (gender, age, place of residence)
• product (for example ATC code, drug name, strength, pack size, included/not included in the pharmaceutical benefits scheme)
• the prescription (for example prescribed quantity/number of packages, strength, date of prescription, date of purchase and type of ordination.)
• the costs (total cost, patient cost, region’s cost and additional patient cost)
• the prescriber (work title, kind of care according to the work-place, education code and specialist education code).

For a complete list of all variables see the variable list (xlsx).

Reporting

All data in the National Prescribed Drug Register comes from the Swedish eHealth Agency. Pharmacies, retailers and wholesalers are obligated to report their sales to the Swedish eHealth Agency. In addition, pharmacies must submit additional information to the Swedish eHealth Agency when a prescribed drug is dispensed. The Swedish eHealth Agency in turn submits information on prescription dispensations to the National Board of Health and Welfare.

The quality of the National Prescribed Drug Register is overall very good. The risk of measurement errors is small since the collection process is largely automated and is based on administrative systems. The Swedish eHealth Agency checks the quality of the sales data that the pharmacies deliver before it is included in the register, but errors and incompletions cannot be completely avoided.

A small proportion of the rows in the National Prescribed Drug Register have negative values for the variables antal, tkost, lankost, patkost, merkost and fddd. This is not a lack of quality but rather how the register is corrected. This may be due to the fact that a drug has been registered in the system but has not been retrieved or that a pharmacy has accepted a repurchase of medicines (e.g. in case of product failure). There may also be misreported transactions that need to be corrected for some reason. The minus rows are used for the register to match when aggregating and summing.

Share

Keytruda is projected to stay the top-ranked drug worldwide based on sales in 2025, with some 31 billion U.S. dollars. This statistic displays the expected top drugs in 2025 based on sales projections as of December 2024. It has to be mentioned that Novo Nordisk's brands Ozempic and Wegovy are, in fact, the same drug (generic name semaglutide), where only dosage and dose form define if it is used for diabetes or weight loss. It is very similar in the case of Eli Lilly's Mounjaro and Zepbound which are basically one and the same drug (generic name tirzepatide). Oncology's dominance in pharmaceutical revenues Cancer treatments are becoming increasingly crucial in the pharmaceutical landscape. Keytruda's projected sales for 2025 underscore this trend, while the drug's revenue increased by more than four billion dollars between 2023 and 2024. This growth is part of a larger pattern in global oncology spending, which exceeded 250 billion U.S. dollars globally in 2024, almost doubling from five years earlier. The substantial investment in cancer treatments is likely to continue, with major pharmaceutical companies like Johnson & Johnson, AstraZeneca, and Merck expected to be the oncology market leaders by 2030. Market dynamics and company performance Merck & Co. has seen its overall revenue increase to 64 billion in 2024, driven largely by its oncology franchise. The company's commitment to innovation is evident in its record-high R&D spending in 2023. This focus on research and development is crucial for maintaining competitiveness in the industry, as demonstrated by the changing rankings of top-selling drugs. For instance, AbbVie's Humira, once a blockbuster, dropped out of the top 10 best-selling drugs in 2024 due to patent expiration, highlighting the constant need for pharmaceutical companies to innovate and develop new products to maintain their market position.

The VA Drug Pricing database contains the current prices for pharmaceuticals purchased by the federal government. These listed prices are based on the Federal Supply Schedule (FSS). This database is mandated by Public Law 102-585, the Veterans Health Care Act of 1992, which sets the maximum amount that a drug may be bought for by the Veterans Health Administration (VHA). The source of this information is contained in printed contracts or data files supplied by the drug manufacturers, representing the pricing agreements between VHA and the manufacturers. Price data is input by the National Acquisition Center (NAC) into the database administered by the Pharmacy Benefits Management Strategic Health Care Group. Information from this database is published on the World Wide Web at the following site: http://www.pbm.va.gov. The users of this database include pharmaceutical manufacturers, drug wholesalers, Office of Inspector General (OIG) and those who purchase pharmaceuticals for the VHA and other government agencies.

Pharmaceutical spending per capita in Canada stood at 1,035 U.S. dollars in 2023 (current prices). In comparison, the United States reported per capita spending of 1,564 U.S. dollars (in 2022). As for medical goods and services in general, the U.S. is among the countries with highest health costs worldwide. The higher costs in the United States are particularly obvious when compared to other high-income, developed countries. Higher drug prices in the U.S.Higher spending on pharmaceuticals is less impacted by higher drug usage by Americans and more by significantly higher drug prices in the United States. While in other countries, drug prices are regulated more or less by governments, the U.S. leaves drug pricing to market competition. As an outcome, the U.S. market is the most profitable for pharmaceutical companies. For example, the price for blockbuster drug Humira was six times higher in the United States than in Germany (2022). Rx drug usage in the U.S.Almost half of all Americans have taken at least one prescription medicine within the preceding month. Generally, women take more prescribed drugs than men, although the difference decreased significantly over the past two decades. In the United States, among the therapeutic areas where spending is the highest are antidiabetics, oncologics, autoimmune, and respiratory diseases. On the other hand, antihypertensives and mental health drugs are the leading classes based on number of prescriptions filled.

This statistic shows the number of pharmaceuticals that were on China's national reimbursement drug list in 2009 (a list that forms the basis of China's basic medical insurance coverage), sorted by pharmaceutical and list type. There were 154 types of traditional Chinese medicine pharmaceuticals on the NRDL's A list in 2009.

This dataset is a list of domestic PIC/S GDP pharmaceutical traders audited by the Food and Drug Administration. The dataset is updated simultaneously with the website of the administration, providing further use for consumers, businesses, or medical professionals.

Editor’s Choice

• The pharmacy market size is expected to be worth around USD 1,750 billion by 2032
• The global prescription drugs market was valued at US$ 1050.26 Mn in 2021 and is projected to register а СРGR of 9.0% by 2031.
• The most prescribed drug category is analgesics (pain relievers), accounting for approximately 24% of total prescriptions.
• Humira (adalimumab) holds the top position as the most prescribed drug by sales, generating a staggering $19.8 billion in sales in 2021.
• Prescription drug expenditure constitutes approximately 18% of the overall healthcare spending in the United States.
• The prevalence of prescription drug abuse affects around 18 million people in the United States aged 12 and older, highlighting the significant impact of this issue on public health.
• Generic drugs dominate the global pharmaceutical market, filling over 70% of all prescriptions, showcasing their widespread utilization and cost-effectiveness.
• Adverse drug reactions (ADRs) remain a concerning aspect of prescription drug use, as they account for 1 in 3 hospital-acquired injuries, emphasizing the importance of drug safety measures.

Projected Global Prescription Drug Revenue (2020-2028)

The General Pharmaceutical Services in England report shows information about community pharmacy contractors (community pharmacies) and appliance contractors in England, and the NHS services they provided It is a National Statistics publication and is the only national level dataset that shows this information. It may be of interest to members of the public, healthcare professionals, policy officials and other stakeholders.

The data provided in this publication comes from NHS Prescription Services, a division of NHS Business Services Authority, NHS England Local Area Teams and NHS Litigation Authority Family Health Services Appeal Unit. The data covers community pharmacy contractors and appliance contractors on the NHS England pharmaceutical list dispensing NHS prescriptions under the NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations.

Global Essential Medicines Database

In June of 2017, we searched the WHO Essential Medicines and Health Products Information Portal, an online repository that contains hundreds of publication on medicines and health products related to WHO priorities, and a full-section dedicated to national essential medicines lists (EMLs). A WHO information specialist actively searched for updated versions of national EMLs, including national formularies, reimbursement lists, and lists based on standard treatment guidelines.

We included all national EMLs that were posted on the WHO’s NEMLs Repository irrespective of publication date and language. When we found more than one national EML from the same country, we used the most recent. We excluded documents that were not EMLs, such as prescribing guidelines. We also included the 20th edition of the WHO Model EML (2017) in this database.

From each EML we abstracted medicines using International Nonproprietary Names (INNs). For medicines whose names were not in English we used the Anatomical Therapeutic Chemical (ATC) classification system, if available, or translated the names with the help of Google Translate. We listed each medicine individually, whether it was part of a combination product or not. We treated as the same medicine bases and their salts (e.g. promethazine hydrochloride and promethazine) as well as different compounds of the same vitamin or mineral (e.g. ferrous fumarate and ferrous sulfate). We excluded diagnostic agents, antiseptics, disinfectants, and saline solutions.

In this database "1" and "0" indicate the presence or absence of the medicine respectively on an EML.

This is the collection associated with list S76 LUXPHARMA Pharmaceuticals Marketed in Luxembourg on the NORMAN Suspect List Exchange.

https://www.norman-network.com/nds/SLE/

This list contains pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de santé, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI: 10.5281/zenodo.4587355

Study design We conducted a cross-sectional study to quantify the number and describe the characteristics of prescription drugs on the Canadian market as of August 23, 2022 with a patient support program defined as services (including but not limited to financial assistance) offered to patients prescribed a specific drug and initiated and funded by the manufacturer. We then conducted a structured content analysis of web-based sources to understand the types and range of supports provided to patients through these programs. We chose to rely exclusively on publicly available data sources to both identify and describe manufacturer-sponsored patient support programs as these are sources currently available to patients when making program enrolment decisions and policymakers seeking to understand the extent and impact of this model of care. Sampling frame Because the European Medicines Association defines a patient support program as services for a specific drug offered by the company holding the marketing authorization, we first sought to identify all drug companies with currently marketed, prescription products in Canada. Between June 27, 2022 and August 23, 2022, two investigators independently extracted the names of all member companies listed on the websites of the three main trade associations for the Canadian pharmaceutical industry (Innovative Medicines Canada, representing the research-based pharmaceutical industry; BIOTECanada, representing the biotechnology industry; and the Canadian Generic Pharmaceutical Association, representing generic drug manufacturers). Because trade association membership is voluntary, we supplemented this list with non-member drug manufacturers identified in previous research. Using the Health Canada Drug Product Database,two investigators independently screened the list of companies and included those with marketed, prescription products and excluded companies that were not drug manufacturers (e.g., law firms) or without currently marketed prescription drugs (e.g., products under development). Discrepancies were resolved through discussion or adjudication by a third author. Sample and variables Using the Health Canada Drug Product Database, one investigator searched each identified drug manufacturer and extracted the product and active ingredient name(s) for all marketed, prescription drugs. We counted a single “drug” as all dosages, formulations, or routes of administration with the same active ingredients and manufacturer since industry patient support programs are brand-specific and do not typically differentiate among these factors. We selected variables that reflect known characteristics of drugs that may be associated with having a patient support program, and for which data were publicly available. One investigator also extracted Schedule D (biologic) status, route(s) of administration, and Level 1 Anatomical Therapeutic Chemical (ATC) code from the Drug Product Database and Product Monograph and identified whether the drug had Orphan Drug Status using the searchable United States database. On the basis of type of Health Canada regulatory review (i.e. innovator or subsequent entry), clinical expertise, and knowledge about the manufacturer, two investigators independently identified the brand status of each drug as brand (i.e. “innovator” products first to market); branded generic (i.e. “subsequent entry” products which are bioequivalent or biosimilar to an existing product on the market, but given a proprietary name); or generic (i.e. “subsequent entry” products which are bioequivalent to an existing product on the market). We classified biosimilars as branded generics. We resolved discrepancies through discussion, and/or adjudication by a third author. Identifying patient support programs and their characteristics Our primary outcome was whether a sampled drug had an associated manufacturer-sponsored patient support program. We defined a patient support program as any combination of services or resources related to medication access, administration, adherence, education, storage, or disposal for patients prescribed a specific product and initiated, sponsored and/or operated by the company holding the product’s marketing authorization. We distinguished patient support programs from “patient assistance programs,” excluding programs that exclusively provided financial assistance (e.g., coupons, co-pay coverage, etc.); expanded or compassionate access programs; risk management programs outlined in the Product Monograph (initiated by the regulator rather than the manufacturer); and programs delivered solely for a clinical study. Two investigators independently performed structured searches on Google (“[company name] AND patient support program AND Canada” and “[drug brand name] AND patient support program AND Canada”) to identify industry sponsored patient support programs in Canada and resolving discrepancies through discussion. Using Zotero, a reference management...

This is the collection associated with list S10 SWISSPHARMA on the NORMAN Suspect List Exchange.

https://www.norman-network.com/nds/SLE/

S10 | SWISSPHARMA | Pharmaceutical List with Consumption Data

Swiss Pharma CSV, XLSX (3/10/2017)

CompTox SWISSPHARMA List

Pharma MS-ready InChIKeys (02/05/2017)

Table S2 from Singer et al. 2016.
DOI: 10.1021/acs.est.5b03332

This dataset is comprised of data submitted to HCAI by prescription drug manufacturers for wholesale acquisition cost (WAC) increases that exceed the statutorily-mandated WAC increase threshold of an increase of more than 16% above the WAC of the drug product on December 31 of the calendar year three years prior to the current calendar year. This threshold applies to prescription drug products with a WAC greater than $40 for a course of therapy. Required WAC increase reports are to be submitted to HCAI within a month after the end of the quarter in which the WAC increase went into effect. Please see the statute and regulations for additional information regarding reporting thresholds and report due dates.

Key data elements in this dataset include the National Drug Code (NDC) maintained by the FDA, narrative descriptions of the reasons for the increase in WAC, and the five-year history of WAC increases for the NDC. A WAC Increase Report consists of 27 data elements that have been divided into two separate Excel data sets: Prescription Drug WAC Increase and Prescription Drug WAC Increase – 5 Year History. The datasets include manufacturer WAC Increase Reports received since January 1, 2019. The Prescription Drugs WAC Increase dataset consists of the information submitted by prescription drug manufacturers that pertains to the current WAC increase of a given report, including the amount of the current increase, the WAC after increase, and the effective date of the increase. The Prescription Drugs WAC Increase – 5 Year History dataset consists of the information submitted by prescription drug manufacturers for the data elements that comprise the 5-year history of WAC increases of a given report, including the amount of each increase and their effective dates.

There are 2 types of WAC Increase datasets below: Monthly and Annual. The Monthly datasets include the data in completed reports submitted by manufacturers for calendar year 2025, as of July 8, 2025. The Annual datasets include data in completed reports submitted by manufacturers for the specified year. The datasets may include reports that do not meet the specified minimum thresholds for reporting.

The Quick Guide explaining how to link the information in each data set to form complete reports is here: https://hcai.ca.gov/wp-content/uploads/2024/03/QuickGuide_LinkingTheDatasets.pdf

The program regulations are available here: https://hcai.ca.gov/wp-content/uploads/2024/03/CTRx-Regulations-Text.pdf

The data format and file specifications are available here: https://hcai.ca.gov/wp-content/uploads/2024/03/Format-and-File-Specifications-version-2.0-ada.pdf

DATA NOTES: Due to recent changes in Excel, it is not recommended that you save these files to .csv format. If you do, when importing back into Excel the leading zeros in the NDC number column will be dropped. If you need to save it into a different format other than .xlsx it must be .txt

DATA UPDATES: Annual datasets of reports from the preceding year are reviewed in the second half of the current year to identify if any revisions or additions have been made since the original release of the datasets. If revisions or additions have been found, an update of the datasets will be released. Datasets will be clearly marked with 'Updated' in their titles for convenient identification. Not all datasets may require an updated release. The review of previously released datasets will only be conducted once to determine if an updated release is necessary. Datasets with revisions or additions that may have been made after the one-time review can be requested. These requests should be sent via email to ctrx@hcai.ca.gov. Due to regulatory changes that went into effect April 1, 2024, reports submitted prior to April 1, 2024, will include the data field "Unit Sales Volume in US" and reports submitted on or after April 1, 2024, will instead include "Total Volume of Gross Sales in US Dollars".

This dataset provides a list of members of the advisory group for prescription drugs and over-the-counter drugs, in order to be used by academic institutions, businesses, the public, etc.

The data set includes the top 25 list for costliest prescribed drugs, most frequently prescribed drugs and the prescribed drugs with the highest monthly median out-of-pocket costs. Each of these top 25 lists are given for commercial plans and are broken out by brand or generic category (i.e., Brand or Generic, Brand, and Generic). The includes National Drug Code (NDC), Drug Name, number of prescriptions, number of individuals, total costs, cost per prescription and monthly median out-of-pocket costs for each NDC in each top 25 list.

This statistic depicts a list of selected FDA-approved prescription drugs, which were later pulled from the U.S. market. The longest running FDA-approved drug which was later recalled from the market was Darvon & Darvocet, between 1955 and 2010, which stayed in the market for 55 years. The reason for the recall was serious toxicity to the heart: between 1981 and 1999 there were over 2,110 deaths reported connected to that drug. According to the Food and Drug Adminitration (FDA), a "drug is removed from the market when its risks outweigh its benefits. A drug is usually taken off the market because of safety issues with the drug that cannot be corrected, such as when it is discovered that the drug can cause serious side effects that were not known at the time of approval."

Rational drug list

Data from Food, Medicine and Health Care Administration and Control Authority of Ethiopia